平消胶囊联合左甲状腺素钠治疗结节性甲状腺肿的效果  

Effect of Pingxiao Capsule Combined with Levothyroxine Sodium in the Treatment of Nodular Goiter

作　　者：刘华朋 杨静[2] 薛榜稳 周倩 王松[1] LIU Huapeng;YANG Jing;XUE Bangwen;ZHOU Qian;WANG Song(Second Ward,Department of Endocrinology,Nanyang Central Hospital,Nanyang 473000,China;Department of Child Respiratory,Nanyang Central Hospital,Nanyang 473000,China)

机构地区：[1]南阳市中心医院内分泌科二病区,河南南阳473000 [2]南阳市中心医院儿童呼吸科,河南南阳473000

出　　处：《河南医学研究》2024年第14期2611-2614,共4页Henan Medical Research

摘　　要：目的分析平消胶囊联合左甲状腺素钠治疗结节性甲状腺肿的效果。方法于2020年3月至2022年9月在南阳市中心医院收集病例展开研究,将92例结节性甲状腺肿患者按随机数字表法分为联合组(46例)与单一组(46例)。单一组接受左甲状腺素钠治疗,联合组加用平消胶囊。对比两组疗效;对比两组治疗前后甲状腺激素水平[游离三碘甲状腺原氨酸(FT_(3))、游离甲状腺素(FT_(4))、促甲状腺激素(TSH)]、结节最大直径、血管内皮生长因子(VEGF)水平、转化生长因子-β_(1)水平(TGF-β_(1))、白细胞介素-1β(IL-1β)水平、白细胞介素-6(IL-6)水平;对比两组不良反应发生率。结果联合组患者总有效率[95.65%(44/46)]较单一组患者[80.43%(37/46)]高(P<0.05)。与治疗前比,两组患者治疗后FT_(3)、FT_(4)均升高,TSH均降低(P<0.05);与单一组患者治疗后比,联合组患者FT_(3)、FT_(4)较高,TSH较低(P<0.05)。与治疗前比,两组患者治疗后结节最大直径均缩短(P<0.05);与单一组患者治疗后比,联合组患者结节最大直径较短(P<0.05)。与治疗前比,两组患者治疗后VEGF均降低,TGF-β_(1)均升高(P<0.05);与单一组患者治疗后比,联合组患者VEGF较低,TGF-β_(1)较高(P<0.05)。与治疗前比,两组患者治疗后IL-1β、IL-6水平均增高(P<0.05);与单一组患者治疗后比,联合组患者IL-1β、IL-6水平较高(P<0.05)。联合组患者不良反应发生率[6.52%(3/46)]与单一组患者[4.35%(2/46)]对比,差异无统计学意义(P>0.05)。结论平消胶囊联合左甲状腺素钠治疗结节性甲状腺肿效果确切,可调节VEGF、TGF-β_(1),能缩小结节,改善甲状腺功能,且安全性良好。Objective To analyze the effect of pingxiao capsule combined with levothyroxine sodium in the treatment of nodular goiter.Methods From March 2020 to September 2022,92 patients with nodular goiter were collected in Nanyang Central Hospital for the study.According to the random number table method,they were divided into the combined group(46 cases)and the single group(46 cases).The single group was treated with levothyroxine sodium,and the combined group was added Pingxiao capsule.The two groups of curative effect was compared.The two groups before and after treatment with thyroid hormone levels[free triiodothyronine(FT_(3))and free thyroxine(FT_(4)),thyroid stimulating hormone(TSH)],nodal diameter and vascular endothelial growth factor(VEGF)level,transforming growth factorβ_(1)level(TGF-β_(1)),interleukin 1β(IL-1β)levels,white interleukin-6(IL-6)levels were compared.The two groups of the incidence of adverse reactions were compared.Results The total effective rate of the combined group[95.65%(44/46)]was higher than that of the single group[80.43%(37/46)](P<0.05).Compared with before treatment,FT_(3)and FT_(4)were increased,and TSH was decreased in the two groups after treatment(P<0.05).Compared with the single group after treatment,FT_(3)and FT_(4)in the combined group were higher,and TSH was lower(P<0.05).Compared before treatment,the maximum diameter of nodules was shortened after treatment in the two groups(P<0.05).Compared with the single group after treatment,the maximum diameter of nodules in the combined group was shorter(P<0.05).Compared with before treatment,VEGF was decreased and TGF-β_(1)was increased in the two groups after treatment(P<0.05).Compared with the single group after treatment,the VEGF level in the combined group was lower and the TGF-β_(1)level was higher(P<0.05).Compared with before treatment,the levels of IL-1βand IL-6 in the two groups were increased after treatment(P<0.05).Compared with the single group after treatment,the levels of IL-1βand IL-6 in the combined group were highe

关 键 词：结节性甲状腺肿 平消胶囊 左甲状腺素钠 

分 类 号：R581.3[医药卫生—内分泌]